



Cytarabine

Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		

Urgency:

- Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

Medication Requested:

- Cytarabine 100mg/5mL solution for injection
 Cytarabine 1g/50ml solution for injection
 Cytarabine 2g/20ml solution for injection
 Cytarabine 500mg/25ml solution for injection

ICD10:

Dose: Frequency of therapy: Duration of therapy:

What is your patient's current height? What is your patient's current weight?

Where will this medication be obtained?

- Accredo Specialty Pharmacy**
 Prescriber's office stock (billing on a medical claim form)
 Other (please specify):
 Retail pharmacy
 Home Health / Home Infusion vendor
 **Cigna's nationally preferred specialty pharmacy

**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557

Facility and/or doctor dispensing and administering medication:

Facility Name: State: Tax ID#: Address (City, State, Zip Code):

- Is the patient a candidate for home infusion? Yes No
 Does the physician have an in-office infusion site? Yes No

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? Yes No

Diagnosis related to use?

- | | |
|--|--|
| <ul style="list-style-type: none"> <input type="checkbox"/> acute lymphoblastic leukemia (ALL, acute lymphocytic leukemia, or acute lymphoid leukemia) <input type="checkbox"/> acute myeloid leukemia (AML, acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia) <input type="checkbox"/> acute promyelocytic leukemia (APL or M3 subtype of AML) <input type="checkbox"/> adult T-cell leukemia/lymphoma (ATLL) <input type="checkbox"/> AIDS related B-cell lymphoma <input type="checkbox"/> Burkitt's lymphoma <input type="checkbox"/> chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) <input type="checkbox"/> diffuse large B-cell lymphoma (DLBCL) <input type="checkbox"/> extranodal NK/T-cell lymphoma, nasal type <input type="checkbox"/> follicular lymphoma (FL) <input type="checkbox"/> hepatosplenic gamma-delta T-cell lymphoma (HGDTCL) <input type="checkbox"/> high-grade B-cell lymphoma | <ul style="list-style-type: none"> <input type="checkbox"/> Histologic Transformation of Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma <input type="checkbox"/> Hodgkin's lymphoma (HL) <input type="checkbox"/> leptomeningeal metastases (carcinomatous meningitis) <input type="checkbox"/> management of chimeric antigen receptor (CAR) T-cell-related toxicities <input type="checkbox"/> mantle cell lymphoma (MCL) <input type="checkbox"/> mycosis fungoides (MF)/Sezary syndrome (SS) <input type="checkbox"/> post-transplant lymphoproliferative disorder (PTLD) <input type="checkbox"/> peripheral T-cell lymphoma <input type="checkbox"/> primary CNS lymphoma <input type="checkbox"/> primary cutaneous CD30+ T-cell lymphoproliferative disorder (examples include lymphomatoid papulosis [LyP] and primary cutaneous anaplastic large-cell lymphoma [ALCL]) <input type="checkbox"/> T cell lymphoma (not otherwise listed) <input type="checkbox"/> other (please specify): |
|--|--|

Clinical Information

(if AML) Is the drug requested being used as part of an alternative non-anthracycline-containing regimen? (Note that anthracyclines include doxorubicin [Adriamycin], daunorubicin, epirubicin [Ellence] and idarubicin [Idamycin PFS], Doxil, Lipodox and Vyxeos)
Yes No

Additional pertinent information (please include disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v071520

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005